432 related articles for article (PubMed ID: 25406731)
21. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
Xu X; Zhang XA; Wang DW
Adv Drug Deliv Rev; 2011 Jul; 63(8):597-609. PubMed ID: 21477627
[TBL] [Abstract][Full Text] [Related]
22. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice.
Deng Y; Edin ML; Theken KN; Schuck RN; Flake GP; Kannon MA; DeGraff LM; Lih FB; Foley J; Bradbury JA; Graves JP; Tomer KB; Falck JR; Zeldin DC; Lee CR
FASEB J; 2011 Feb; 25(2):703-13. PubMed ID: 21059750
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease.
Theken KN; Schuck RN; Edin ML; Tran B; Ellis K; Bass A; Lih FB; Tomer KB; Poloyac SM; Wu MC; Hinderliter AL; Zeldin DC; Stouffer GA; Lee CR
Atherosclerosis; 2012 Jun; 222(2):530-6. PubMed ID: 22503544
[TBL] [Abstract][Full Text] [Related]
24. Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner.
Cizkova K
Toxicol Appl Pharmacol; 2018 Sep; 355():156-163. PubMed ID: 29960002
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man.
Revermann M
Curr Opin Pharmacol; 2010 Apr; 10(2):173-8. PubMed ID: 20079692
[TBL] [Abstract][Full Text] [Related]
26. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR).
Michaelis UR; Fisslthaler B; Medhora M; Harder D; Fleming I; Busse R
FASEB J; 2003 Apr; 17(6):770-2. PubMed ID: 12586744
[TBL] [Abstract][Full Text] [Related]
27. Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids.
Shahabi P; Siest G; Visvikis-siest S
Drug Metab Rev; 2014 Feb; 46(1):33-56. PubMed ID: 24040964
[TBL] [Abstract][Full Text] [Related]
28. Beyond detoxification: a role for mouse mEH in the hepatic metabolism of endogenous lipids.
Marowsky A; Meyer I; Erismann-Ebner K; Pellegrini G; Mule N; Arand M
Arch Toxicol; 2017 Nov; 91(11):3571-3585. PubMed ID: 28975360
[TBL] [Abstract][Full Text] [Related]
29. Cytochrome p450 epoxygenase promotes human cancer metastasis.
Jiang JG; Ning YG; Chen C; Ma D; Liu ZJ; Yang S; Zhou J; Xiao X; Zhang XA; Edin ML; Card JW; Wang J; Zeldin DC; Wang DW
Cancer Res; 2007 Jul; 67(14):6665-74. PubMed ID: 17638876
[TBL] [Abstract][Full Text] [Related]
30. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.
Yu Z; Xu F; Huse LM; Morisseau C; Draper AJ; Newman JW; Parker C; Graham L; Engler MM; Hammock BD; Zeldin DC; Kroetz DL
Circ Res; 2000 Nov; 87(11):992-8. PubMed ID: 11090543
[TBL] [Abstract][Full Text] [Related]
31. High potassium intake enhances the inhibitory effect of 11,12-EET on ENaC.
Sun P; Lin DH; Yue P; Jiang H; Gotlinger KH; Schwartzman ML; Falck JR; Goli M; Wang WH
J Am Soc Nephrol; 2010 Oct; 21(10):1667-77. PubMed ID: 20595684
[TBL] [Abstract][Full Text] [Related]
32. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition.
Fang X; Kaduce TL; Weintraub NL; Harmon S; Teesch LM; Morisseau C; Thompson DA; Hammock BD; Spector AA
J Biol Chem; 2001 May; 276(18):14867-74. PubMed ID: 11278979
[TBL] [Abstract][Full Text] [Related]
33. EETs/sEH in diabetes and obesity-induced cardiovascular diseases.
Huang H; Weng J; Wang MH
Prostaglandins Other Lipid Mediat; 2016 Sep; 125():80-9. PubMed ID: 27184755
[TBL] [Abstract][Full Text] [Related]
34. Increased Soluble Epoxide Hydrolase in Human Gestational Tissues from Pregnancies Complicated by Acute Chorioamnionitis.
Hung TH; Chen SF; Wu CH; Kao CC; Wu CP
Mediators Inflamm; 2019; 2019():8687120. PubMed ID: 31885501
[TBL] [Abstract][Full Text] [Related]
35. Soluble epoxide hydrolase limits mechanical hyperalgesia during inflammation.
Brenneis C; Sisignano M; Coste O; Altenrath K; Fischer MJ; Angioni C; Fleming I; Brandes RP; Reeh PW; Woolf CJ; Geisslinger G; Scholich K
Mol Pain; 2011 Oct; 7():78. PubMed ID: 21970373
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptor ɑ (PPARɑ)-cytochrome P450 epoxygenases-soluble epoxide hydrolase axis in ER + PR + HER2- breast cancer.
Tauber Z; Koleckova M; Cizkova K
Med Mol Morphol; 2020 Sep; 53(3):141-148. PubMed ID: 31823010
[TBL] [Abstract][Full Text] [Related]
37. Epoxyeicosatrienoic acid pathway in human health and diseases.
Bellien J; Joannides R
J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468
[TBL] [Abstract][Full Text] [Related]
38. Expression of cytochrome P450 arachidonic acid epoxygenase 2J2 in human tumor tissues and cell lines.
Jiang JG; Fu XN; Chen CL; Wang DW
Ai Zheng; 2009 Feb; 28(2):93-6. PubMed ID: 19550113
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of soluble epoxide hydrolase attenuates airway remodeling in a chronic asthma model.
Jiang JX; Guan Y; Shen HJ; Jia YL; Shen J; Zhang LH; Liu Q; Zhu YL; Xie QM
Eur J Pharmacol; 2020 Feb; 868():172874. PubMed ID: 31866410
[TBL] [Abstract][Full Text] [Related]
40. Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles.
Gauthier KM; Olson L; Harder A; Isbell M; Imig JD; Gutterman DD; Falck JR; Campbell WB
Am J Physiol Renal Physiol; 2011 Oct; 301(4):F765-72. PubMed ID: 21753077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
